Linglan Tu
Impact in
- Pharmaceutical Science top 5%
- Advanced Drug Delivery Systems
Papers in
-
- Advanced Drug Delivery Systems 3
-
- DNA Repair Mechanisms 3
- Mechanisms of cancer metastasis 3
- PI3K/AKT/mTOR signaling in cancer 2
- Ubiquitin and proteasome pathways 2
- Co-authors
- Xiaoliang Zheng (21 shared papers)Lina Yin (4 shared papers)Xiaoju Wang (6 shared papers)Laijin Tian (5 shared papers)Shirong Zhang (3 shared papers)Guang Liang (6 shared papers)Jingjing Zhang (3 shared papers)Dongmei Yan (5 shared papers)
- Journals
- Applied Organometallic Chemistry (3 papers)Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2 papers)European Journal of Medicinal Chemistry (2 papers)Cellular Signalling (2 papers)Biomedicine & Pharmacotherapy (2 papers)
- Partner nations
- China
In The Last Decade
Linglan Tu
35 papers receiving 452 citations
Peers
Comparison fields: 5 of 61
- Pharmaceutical Science 64
- Drug Discovery 1
- Biomaterials 39
- Cancer Research 38
- Oncology 58
Countries citing papers authored by Linglan Tu
This map shows the geographic impact of Linglan Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linglan Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linglan Tu more than expected).
Fields of papers citing papers by Linglan Tu
This network shows the impact of papers produced by Linglan Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linglan Tu. The network helps show where Linglan Tu may publish in the future.
Co-authors
The 25 scholars most cited alongside Linglan Tu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 68 | |
| 2 | 2017 | 45 | |
| 3 | 2021 | 29 | |
| 4 | 2023 | 29 | |
| 5 | 2023 | 26 | |
| 6 | 2021 | 24 | |
| 7 | 2023 | 23 | |
| 8 | 2011 | 22 | |
| 9 | 2008 | 19 | |
| 10 | 2018 | 17 | |
| 11 | 2013 | 12 | |
| 12 | 2022 | 11 | |
| 13 | 2023 | 11 | |
| 14 | 2023 | 10 | |
| 15 | 2023 | 10 | |
| 16 | 2017 | 9 | |
| 17 | 2024 | 9 | |
| 18 | 2024 | 9 | |
| 19 | 2024 | 8 | |
| 20 | 2011 | 7 |
About Linglan Tu
Linglan Tu is a scholar working on Pharmaceutical Science, Molecular Biology, Hepatology, Organic Chemistry and Cancer Research, having authored 36 papers that have together received 455 indexed citations. Recurring topics across this work include Organometallic Compounds Synthesis and Characterization (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers), DNA Repair Mechanisms (3 papers), Mechanisms of cancer metastasis (3 papers), Advanced Drug Delivery Systems (3 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), Ubiquitin and proteasome pathways (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Pharmaceutical Science (64 citations), Drug Discovery (1 citation), Biomaterials (39 citations), Cancer Research (38 citations) and Oncology (58 citations). Linglan Tu has collaborated with scholars based in China. Frequent co-authors include Xiaoliang Zheng, Lina Yin, Xiaoju Wang, Laijin Tian, Shirong Zhang, Guang Liang, Jingjing Zhang, Dongmei Yan, Lucheng Zhu and Lingfeng Chen. Their work appears in journals such as Applied Organometallic Chemistry, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, European Journal of Medicinal Chemistry, Cellular Signalling and Biomedicine & Pharmacotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.